Related Experiment Video
Updated: Mar 14, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
671
Albiglutide: a unique GLP-1 receptor agonist
1a The Rose Salter Medical Research Foundation , Omaha , NE , USA.
Expert Opinion on Biological Therapy
|September 29, 2016
Summary
Albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), offers a distinct profile with fewer gastrointestinal side effects and renal safety. However, its efficacy in lowering HbA1c and aiding weight loss is less than competitors.
Area of Science:
- Pharmacology and Therapeutics
- Endocrinology
- Diabetes Mellitus Management
Background:
- Albiglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) administered weekly.
- Its unique chemical structure differentiates it from other GLP-1 RAs.
- The review focuses on pharmacokinetic, pharmacodynamic, and clinical properties.
Purpose of the Study:
- To review the pharmacokinetic and pharmacodynamic properties of albiglutide.
- To discuss the clinical effects and safety profile of albiglutide.
- To assess its place in diabetes management compared to other GLP-1 RAs.
Main Methods:
- Literature search of PubMed.
- Analysis of European Union and US Food and Drug Administration approval documents.
- Expert opinion synthesis on clinical data.
Main Results:
- Albiglutide demonstrates less gastrointestinal intolerance and is safe in renal failure.
- Achieves up to 1% HbA1c reduction, which is lower than some competing GLP-1 RAs.
- Minimal weight reduction benefit compared to other GLP-1 RAs.
- Concerns noted regarding pancreatitis and injection site reactions (2% discontinuation).
Conclusions:
- Albiglutide presents a favorable gastrointestinal and renal safety profile.
- Its efficacy in glycemic control and weight reduction is moderate compared to other GLP-1 RAs.
- Ongoing long-term studies will clarify its role in managing cardiovascular risk in diabetic patients.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
804
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
804
01:23Dipeptidyl Peptidase 4 Inhibitors
860
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
746
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
746
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
796
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
796
01:17Drugs for Treatment of Diarrhea-Predominant IBS
833
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
833